Datapoint: Pfizer, J&J Settle Remicade-Inflectra Legal Battle

Pfizer and Johnson & Johnson have settled their legal battle over anticompetitive practices marketing their two immunology drugs, J&J’s blockbuster Remicade and Pfizer’s biosimilar Inflectra, according to a report from the American Journal of Managed Care’s Center for Biosimilars. While terms of the settlement were not disclosed, Pfizer will continue to market Inflectra. For the treatment of ulcerative colitis, Remicade remains advantaged over Inflectra, holding covered or better status for 59% of all insured lives under the pharmacy benefit and 91% under the medical benefit. Meanwhile, Inflectra is covered or better for 50% of lives under the pharmacy benefit and 90% under the medical benefit.

SOURCE: MMIT Analytics, as of 7/28/21

0 Comments

AIS Health Staff

Related Posts

https://www.mmitnetwork.com/wp-content/uploads/2021/08/post-default-img.jpg
October 18

Datapoint: AmeriHealth Caritas to Enter Exchange Market

Read More
https://www.mmitnetwork.com/wp-content/uploads/2021/09/wordpress-featured-image-datapoints.jpg
October 14

Datapoint: Ochsner to Launch MA Org in Louisiana

Read More
https://www.mmitnetwork.com/wp-content/uploads/2021/09/wordpress-featured-image-datapoints.jpg
October 13

Datapoint: Three States to Launch New Exchange Marketplaces

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today